Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Heart Lung Circ ; 31(7): 1029-1036, 2022 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-35337734

RESUMO

OBJECTIVES: The Improved Assessment of Chest pain Trial (IMPACT) pathway is an accelerated strategy for the assessment of emergency patients presenting with suspected acute coronary syndrome (ACS). The objective of this study was to report outcomes for Aboriginal and Torres Strait Islander patients deemed low-, intermediate-, or high-risk according to this pathway. DESIGN: This was a prospective observational trial conducted between November 2017 and December 2019. SETTING: Regional hospital in Far North Queensland. PARTICIPANTS: Aboriginal and Torres Strait Islander people presenting to the Emergency Department with suspected ACS were asked to participate. Participants were stratified as low-, intermediate- or high-risk of ACS according to the IMPACT pathway. High-and intermediate risk patients were managed according to the IMPACT pathway. Management of low-risk patients included additional inpatient cardiac testing, which was not part of the original IMPACT pathway. MAIN OUTCOME MEASURES: The primary outcome was acute coronary syndrome within 30-days. Secondary outcomes included length of stay and prevalence of objective testing. RESULTS: A total of 155 participants were classified as either at low-risk (n=18 11.6%), intermediate-risk (n=87 56.1%), or high-risk (n=50 32.3%) of ACS. Thirty-day (30-day) ACS occurred in 29 (18.6%) patients, which included 26 (52.0%) high-risk patients and three (3.4%) intermediate-risk patients. No patients in the low-risk group were diagnosed with ACS during their index presentation or by 30-days. Median hospital length-of-stay was 11.9 hours (interquartile range [IQR] 5.3-20.2 hrs) for low- and 15.5 hours (IQR 5.9-29.2 hrs) for intermediate-risk patients. CONCLUSION: The IMPACT pathway, which has been associated with reduced LOS in other settings, could be safely implemented for patients of Aboriginal and Torres Strait Islander origin, classifying two-thirds as low- or intermediate risk. However, a clinically significant proportion of Aboriginal and Torres Strait Islander patients experience cardiac events, which supports the need to provide early objective testing for coronary artery disease.


Assuntos
Síndrome Coronariana Aguda , Havaiano Nativo ou Outro Ilhéu do Pacífico , Síndrome Coronariana Aguda/diagnóstico , Serviço Hospitalar de Emergência , Humanos , Prevalência , Queensland/epidemiologia
3.
Emerg Med Australas ; 35(3): 442-449, 2023 06.
Artigo em Inglês | MEDLINE | ID: mdl-36410371

RESUMO

OBJECTIVES: To describe the demographics, presentation characteristics, clinical features and cardiac outcomes for Aboriginal and Torres Strait Islander patients who present to a regional cardiac referral centre ED with suspected acute coronary syndrome (ACS). METHODS: This was a single-centre observational study conducted at a regional referral hospital in Far North Queensland, Australia from November 2017 to September 2018 and January 2019 to December 2019. Study participants were 278 Aboriginal and Torres Strait Islander people presenting to an ED and investigated for suspected ACS. The main outcome measure was the proportion of patients with ACS at index presentation and differences in characteristics between those with and without ACS. RESULTS: ACS at presentation was diagnosed in 38.1% of patients (n = 106). The mean age of patients with ACS was 53.5 years (SD 9.5) compared with 48.7 years (SD 12.1) in those without ACS (P = 0.001). Patients with ACS were more likely to be male (63.2% vs 39.0%, P < 0.001), smokers (70.6% vs 52.3%, P = 0.002), have diabetes (56.6% vs 38.4%, P = 0.003) and have renal impairment (24.5% vs 10.5%, P = 0.002). CONCLUSIONS: Aboriginal and Torres Strait Islander patients with suspected ACS have a high burden of traditional cardiac risk factors, regardless of whether they are eventually diagnosed with ACS. These patients may benefit from assessment for coronary artery disease regardless of age at presentation.


Assuntos
Síndrome Coronariana Aguda , Povos Aborígenes Australianos e Ilhéus do Estreito de Torres , Humanos , Masculino , Pessoa de Meia-Idade , Feminino , Síndrome Coronariana Aguda/diagnóstico , Austrália , Queensland/epidemiologia , Encaminhamento e Consulta
4.
ANZ J Surg ; 74(10): 921-5, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15456454

RESUMO

The management of any surgical condition in a haemophilia patient is a challenging problem for the surgeon. It is particularly difficult if the patient presents in extremis, with no apparent cause for their collapse. We report a case of successful management of spontaneous splenic rupture in a severe haemophiliac, and review the literature associated with this unusual condition.


Assuntos
Hemofilia A/complicações , Esplenectomia , Ruptura Esplênica/complicações , Ruptura Esplênica/cirurgia , Adulto , Humanos , Masculino , Fatores de Risco , Ruptura Espontânea , Índice de Gravidade de Doença
6.
Toxicon ; 55(2-3): 646-9, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-19647759

RESUMO

We report a 60 year old male bitten by snakes from the Acanthophis genus (Death adder) on two occasions who developed high titres of human IgG antibodies to Acanthophis venom detected at the time of the second bite. The patient was bitten by Acanthophis antarcticus (common death adder) on the first occasion, developed non-specific systemic effects and did not receive antivenom. Three months later he was bitten by Acanthophis praelongus (northern death adder) and he developed significant local myotoxicity associated with a moderate rise in the creatine kinase (maximum 4770 U/L). He was given antivenom 55 h after the bite and recovered over several days. Death adder venom was detected in serum at the time of the first bite, but not the second bite. Human IgG antibodies to death adder were detected on the second admission but not the first. However, despite the presence of antibodies to death adder venom and free venom not being detected, the patient still developed significant local myotoxicity.


Assuntos
Antivenenos/sangue , Imunoglobulina G/imunologia , Mordeduras de Serpentes/imunologia , Venenos de Serpentes/imunologia , Animais , Antivenenos/uso terapêutico , Creatina Quinase/sangue , Diabetes Mellitus Tipo 2/complicações , Edema/etiologia , Edema/terapia , Humanos , Masculino , Pessoa de Meia-Idade , Curativos Oclusivos , Dor/etiologia , Manejo da Dor , Mordeduras de Serpentes/terapia , Viperidae/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA